Interferon β in multiple sclerosis: Is IL-12 suppression the key?

Immunology Today

Volumn 21, Issue 1, 2000, Pages 24-28

  Karp, Christopher L ^a   Biron, Christine A ^b   Irani, David N ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; CD4 ANTIGEN; CELL SURFACE RECEPTOR; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; MESSENGER RNA; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS; DEMYELINATING DISEASE; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

EID: 0034044769     PISSN: 01675699     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5699(99)01541-8     Document Type: Note

References (34)

1. 1 Martin, R. and McFarland, H.F. (1996) Experimental immunotherapies for multiple sclerosis. Springer Semin. Immunopathol. 18, 1-24
2. 2 Rudick, R.A. et al. (1997) Management of multiple sclerosis. New Engl. J. Med. 337, 1604-1611
3. 3 Durelli, L. et al. (1994) Chronic systemic high-dose recombinant interferon γ-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon γ production in relapsing-remitting multiple sclerosis. Neurology 44, 406-413
4. 4 European Study Group on Interferon Beta-1b in Secondary Progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352, 1491-1497
5. 5 Hall, G.L. et al. (1997) β-interferon and multiple sclerosis. Trends Neurosci. 20, 63-67
6. 6 Arnason, B.G.W. et al. (1996) Mechanisms of action of interferon-β in multiple sclerosis. Springer Semin. Immunopathol. 18, 125-148
7. 7 Bright, J.J. et al. (1998) Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis. J. Neuroimmunol. 82, 22-30
8. 8 Issazadeh, S. et al. (1995) Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β. J. Neuroimmunol. 61, 205-212
9. 9 Leonard, J.P. et al. (1995) Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181, 381-386
10. 10 Leonard, J.P. et al. (1997) Regulation of the inflammatory response in animal models of multiple sclerosis by interleukin-12. Crit. Rev. Immunol. 17, 545-553
11. 11 Segal, B.M. and Shevach, E.M. (1996) IL-12 unmasks latent autoimmune disease in resistant mice. J. Exp. Med. 184, 771-775
12. 12 Segal, B.M. et al. (1998) An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187, 537-546
13. 13 Constantinescu, C.S. et al. (1998) Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J. Immunol. 161, 5097-5104
14. 14 Smith, T. et al. (1997) Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat Am. J. Pathol. 150, 1909-1917
15. 15 Ferber, I.A. et al. (1996) Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156, 5-7
16. 16 Wills-Karp, M. et al. (1998) Interleukin-13: central mediator of allergic asthma. Science 282, 2258-2261
17. 17 Waldburger, K.E. et al. (1996) Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12: preferential expansion of interferon-γ-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immunomodulatory mechanisms. Am. J. Pathol. 148, 375-382
18. 18 Merrill, J.E. et al. (1993) Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151, 2132-2141
19. 19 Windhagen, A. et al. (1995) Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182, 1985-1996
20. 20 van Boxel-Dezaire, A.H.H. et al. (1999) Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. 45, 695-703
21. + T cells via CD40 ligand. Proc. Natl. Acad. Sci. U. S. A. 94, 599-603
22. 22 Gerritse, K. et al. (1996) CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 93, 2499-2504
23. 23 Comabella, M. et al. (1998) Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest. 102, 671-678
24. 24 Nicoletti, F. et al. (1996) Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J. Neuroimmunol. 70, 87-90
25. 25 Fassbender, K. et al. (1998) Increased release of interleukin-12p40 in MS: association with intracerebral inflammation. Neurology 51, 753-758
26. 26 Ferrante, P. et al. (1998) Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J. Immunol. 160, 1514-1521
27. 27 Cousens, L.P. et al. (1997) Interferon-α/β inhibition of interleukin 12 and interferon-γ production in vitro and endogenously during viral infection. Proc. Natl. Acad. Sci. U. S. A. 94, 634-639
28. 28 McRae, B.L. et al. (1998) Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J. Immunol. 160, 4298-4304
29. 29 Rudick, R.A. et al. (1998) In vivo effects of interferon β-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 50, 1294-1300
30. 30 Rogge, L. et al. (1997) Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med. 185, 825-831
31. 31 Cho, S.S. et al. (1996) Activation of STAT4 by IL-12 and IFN-α: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J. Immunol. 157, 4781-4789
32. 32 Parronchi, P. et al. (1996) Effects of interferon-α on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur. J. Immunol. 26, 697-703
33. 33 McRae, B.L. et al. (1997) Human recombinant interferon-β influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors. Eur. J. Immunol. 27, 2650-2656
34. 34 Cousens, L.P. et al. (1999) Two roads diverged: IFN-α/β-and IL-12-mediated pathways in promoting T cell IFN-γ responses during viral infection. J. Exp. Med. 189, 1315-1327